Furthermore, a recent study reported the overexpression of a cancerous inhibitor of PP2A (CIP2A; an endogenous inhibitor of PP2A) in the AD brain that allows tau phosphorylation and drives the AD pathogenesis [97]. This evidence concerns the gene MAPT and Alzheimer disease.